February 17th 2025
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non-Smal...
February 27, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
CMS Proposes Actions to Lower Prescription Drug Costs: 4 Things to Know
December 12th 2018In an effort to lower prescription drug prices, CMS unveiled proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. Here’s a closer look at what CMS’ provisions entail and how they help accomplish the Administration’s four strategies.
Read More
New Reimbursement May Level Playing Field for Biosimilars
May 21st 2018The new Bipartisan Budget Act of 2018 (to be in effect on January 2019) institute new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.
Read More